ArticlebioRxiv : the preprint server for biology2025
Expansion of DNA-Encoded Library Hits Using Generative Chemistry and Ultra-Large Compound Catalogs.
Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
DNA-encoded libraries (DELs) are powerful tools for initial hit identification, yet the combinatorial chemistries and building block choices used in their construction can restrict chemical space coverage and hit drug-likeness, limiting efficient hit expansion. Generative artificial intelligence (AI), by contrast, can in principle explore drug-like chemical space around any given compound, but it often struggles with the synthesizability of generated molecules and requires a set of validated hits to initiate exploration. Here, we present a synergistic methodology that overcomes these mutual limitations by leveraging experimentally validated DEL data to initialize and bias an AI-powered virtual screening pipeline, expanding initial DEL hits with both de novo and purchasable compounds from ultra-large chemical libraries. Using this approach, we identified novel, commercially available hits from the Enamine REAL Space for the chromatin reader protein 53BP1 and validated them in a time-resolved fluorescence resonance energy transfer (TR-FRET) displacement assay. Three compounds demonstrated TR-FRET IC50 values ≤50 μM, while 11 exhibited IC50 values ≤100 μM. Critically, the AI-nominated hits exhibited greater chemical diversity, improved drug-likeness, and were readily purchasable off-the-shelf compared to compounds from the initial DEL selection. This work demonstrates a streamlined platform in which empirical DEL data and generative chemistry models are combined to enable rapid hit expansion from initially screened libraries into diverse, commercially available chemical matter.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.